Purine metabolism encompasses the de novo synthesis, salvage, and degradation of purine nucleotides. Purines are essential components of DNA and RNA, ATP and GTP, coenzymes including NAD+ and FAD, and signaling molecules such as cAMP and cGMP.
The Purine Ring
The purine ring system consists of a pyrimidine ring fused to an imidazole ring. The nine atoms of the purine ring are derived from multiple precursors. Glycine contributes carbons 4 and 5 and nitrogen 7. Glutamine provides nitrogens 3 and 9. Aspartic acid donates nitrogen 1. Formate from folate metabolism provides carbons 2 and 8. The final carbon, carbon 6, comes from bicarbonate. This biosynthetic origin was established by the classic nutritional studies of Buchanan and Greenberg using isotopic tracers.
De Novo Purine Synthesis
Purine synthesis builds the ring system stepwise on a ribose-5-phosphate scaffold, unlike pyrimidine synthesis where the ring is formed before ribose attachment. The pathway begins with ribose-5-phosphate, which is activated to 5-phosphoribosyl-1-pyrophosphate by PRPP synthetase. PRPP is a central metabolite that links carbohydrate and nucleotide metabolism and is consumed in both purine and pyrimidine synthesis.
The first committed step of purine synthesis is the formation of 5-phosphoribosylamine from PRPP and glutamine, catalyzed by amidophosphoribosyltransferase. This enzyme is inhibited by the end products IMP, AMP, and GMP. Ten additional reactions convert PRA to inosine monophosphate. The pathway consumes four ATP equivalents, with several steps involving ATP-dependent phosphorylations.
Conversion to AMP and GMP
IMP is the branch point for AMP and GMP synthesis. Adenylosuccinate synthetase condenses IMP with aspartate, using GTP as the energy source, to form adenylosuccinate. Adenylosuccinate lyase then eliminates fumarate to produce AMP. The formation of AMP requires GTP, creating a regulatory link between purine and GTP pools.
IMP dehydrogenase oxidizes IMP to xanthosine monophosphate, consuming NAD+ and producing NADH. GMP synthetase then aminates XMP using glutamine and ATP. This branch uses ATP, creating a reciprocal relationship between AMP and GMP synthesis. The balance between AMP and GMP synthesis is regulated by the guanine and adenine nucleotides as allosteric effectors of the branching enzymes.
Purine Salvage
Salvage pathways recycle free purine bases, which is energetically more efficient than de novo synthesis. Hypoxanthine-guanine phosphoribosyltransferase converts hypoxanthine to IMP and guanine to GMP, using PRPP as the phosphoribosyl donor. Adenine phosphoribosyltransferase converts adenine to AMP.
The purine salvage pathway is particularly important in tissues with limited de novo synthesis capacity, including erythrocytes, leukocytes, and the brain. HGPRT deficiency causes Lesch-Nyhan syndrome, an X-linked disorder characterized by hyperuricemia, gout, neurological dysfunction, and self-injurious behavior. The deficiency prevents purine salvage, causing PRPP accumulation and accelerated de novo synthesis.
Purine Degradation
Purine degradation proceeds from nucleotides to nucleosides to free bases to uric acid. AMP is deaminated to IMP by AMP deaminase, then dephosphorylated to inosine by 5-prime nucleotidase. Purine nucleoside phosphorylase cleaves inosine to hypoxanthine and ribose-1-phosphate. Guanine is deaminated to xanthine by guanase. Xanthine oxidase, a molybdenum-containing flavoprotein, oxidizes hypoxanthine to xanthine and xanthine to uric acid, producing hydrogen peroxide as a byproduct.
In most mammals, uricase further oxidizes uric acid to allantoin, which is more water-soluble. Humans lack uricase due to a mutation that occurred during primate evolution, making uric acid the final excretion product. Uric acid has limited solubility, and its crystallization in joints causes gout.
Regulation
Like many metabolic pathways, purine synthesis is regulated by feedback inhibition and by the availability of PRPP. Amidophosphoribosyltransferase is the major control point, inhibited by AMP and GMP and activated by PRPP. PRPP synthetase is inhibited by ADP and GDP. The branching enzymes are reciprocally regulated: high GTP promotes AMP synthesis, while high ATP promotes GMP synthesis.
